FIGURE 2.

Effect of cumulative cisplatin dose on cisplatin‐induced tinnitus, hearing loss, and peripheral sensory neuropathy. (A) Boxplot showing hearing thresholds by cumulative cisplatin dose group (<300, 300, 400, and >400 mg/m²) illustrates significantly increased risk of hearing loss in patients treated with doses 400 mg/m² compared to 300 and >400 mg/m² compared to 400 mg/m²; (B) bar plot showing the frequency of tinnitus by cumulative cisplatin dose group demonstrated significantly increased risk of tinnitus in doses >400 mg/m²‐treated‐survivors compared to 400 mg/m²‐treated‐survivors. (C) Bar plot showing the frequency of severe peripheral neuropathy by cumulative cisplatin dose group illustrates significantly increased risk of peripheral neuropathy in patients treated with doses 400 mg/m² compared to 300 mg/m²‐treated‐survivors. The number of subjects per category is presented on the x axis under the dose group label. *p < 0.05; **p < 0.005